GENITOURINARY CANCERS

Ryan Werntz, MD, urologist, Oregon Health and Science University, discusses the significance of prostate-specific antigen (PSA) screening by primary care physicians.

The anti-PDL1 agent, atezolizumab (MPDL3280A) may effectively shrink tumors in patients with locally advanced or metastatic urothelial bladder cancer in the second-line setting, according to a statement from the immunotherapy’s developer, Genentech.

Results from the phase III METEOR study showed that treatment with cabozantinib (Cometriq) improved progression-free survival (PFS) and overall survival (OS) compared with everolimus (Afinitor) in previously treated patients with metastatic renal cell carcinoma (mRCC).

According to findings from a phase II study released by Amgen, monotherapy with blinatumomab (Blincyto) showed promising complete remission (CR) or CR with partial hematological recovery (CRh) rates in adult patients with relapsed or refractory Philadelphia chromosome-positive (Ph+) B cell precursor acute lymphoblastic leukemia (ALL).

Howard M. Sandler, MD, MS, FASTRO, Chair, Radiation Oncology, Ronald H. Bloom Family Chair, Cancer Therapeutics, Cedars Sinai, discusses the significance of a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.

Scott T. Tagawa, MD, MS, medical director, Genitourinary Oncology Research Program, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses the baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC).

Metastatic Prostate Cancer

Metastatic Prostate Cancer